Trial Profile
OMICC: OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 18 Nov 2021
Price :
$35
*
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications Adenocarcinoma; Colon cancer
- Focus Therapeutic Use
- Acronyms OMICC
- 10 Nov 2021 Planned End Date changed from 30 Nov 2023 to 30 Nov 2021.
- 10 Nov 2021 Planned End Date changed from 1 Sep 2023 to 30 Nov 2023.
- 10 Nov 2021 Planned primary completion date changed from 1 Sep 2021 to 30 Nov 2021.